5 citations
,
August 1998 in “PubMed” Intravenous cyclophosphamide effectively treated steroid-resistant lupus cystitis and peritonitis.
137 citations
,
December 2006 in “Arthritis Research & Therapy” Mycophenolate mofetil is safer and more effective than cyclophosphamide for treating lupus nephritis.
January 2010 in “DOAJ (DOAJ: Directory of Open Access Journals)” IV cyclophosphamide effectively treated severe lupus nephritis in Indian patients, but longer follow-up is needed.
11 citations
,
March 2010 in “PubMed” IV cyclophosphamide effectively treated severe lupus nephritis in Indian patients.
86 citations
,
June 2018 in “Cochrane library” Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.
5 citations
,
October 2001 in “British Journal of Ophthalmology” Sulphadiazine can cause crystals to form in urine.
2 citations
,
January 2012 in “PubMed” Mycophenolate mofetil is effective for treating severe lupus nephritis in children.
Tjalma Syndrome is a rare condition in people with lupus, causing fluid buildup and high CA-125 levels, but not due to tumors.
September 2024 in “Indian Journal of Dermatology Venereology and Leprology” Mesotherapy with bicalutamide has limited effectiveness for female hair loss.
April 2023 in “Journal of Investigative Dermatology” PX-12 may help treat psoriasis by blocking inflammation and cell death.
June 2022 in “Mayo Clinic Proceedings” The man was diagnosed with stage III multiple myeloma and treated to improve kidney function.
July 2025 in “Journal of Investigative Dermatology” Upadacitinib effectively treats pyoderma gangrenosum.
80 citations
,
January 1995 in “The Nephron journals/Nephron journals” The treatment was effective for lupus nephritis with manageable side effects.
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
39 citations
,
September 2015 in “Clinical Therapeutics” Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
March 2005 in “Journal of The American Academy of Dermatology” Mycophenolate mofetil improved skin condition in a man with nephrogenic fibrosing dermopathy.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
42 citations
,
July 2021 in “Frontiers in Medicine” Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
1 citations
,
November 1991 in “PubMed” Immunoadsorption successfully treated a man's resistant polymyositis.
January 2008 in “Zhonghua linchuang mianyi he biantai fanying zazhi” The treatment with Shunyou and prednisone is effective and safe for lupus nephritis.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
1 citations
,
April 2023 in “Heliyon” Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
3 citations
,
February 2019 in “Journal of endourology case reports” Polypoid cystitis can mimic bladder cancer but can be effectively treated with surgery, stents, and medication.
December 2022 in “Jurnal Farmasi Klinik Base Practice” Cyclophosphamide helped 59.4% of children with steroid-resistant nephrotic syndrome but caused side effects in 40.6%.
November 2012 in “Journal of Clinical Pathology” October 1984 in “Kidney international” The patient had complex urinary tract issues and ambiguous genitalia, with physical features suggesting a hormonal imbalance.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.